S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
S&P 500   3,960.50 (-0.08%)
DOW   33,702.87 (-0.23%)
QQQ   284.46 (+0.21%)
AAPL   144.23 (+1.11%)
MSFT   246.97 (-0.17%)
META   116.93 (+1.39%)
GOOGL   93.63 (-0.09%)
AMZN   89.46 (-0.99%)
TSLA   180.12 (+3.85%)
NVDA   172.99 (+0.76%)
NIO   12.84 (-4.25%)
BABA   92.36 (-1.92%)
AMD   69.64 (-1.18%)
T   19.21 (+0.47%)
MU   55.52 (+0.58%)
CGC   2.94 (-4.85%)
F   13.24 (+0.91%)
GE   82.27 (-1.63%)
DIS   94.05 (+1.62%)
AMC   5.84 (-3.79%)
PYPL   74.18 (-0.05%)
PFE   51.88 (+0.19%)
NFLX   325.08 (+4.78%)
NASDAQ:CLLS

Cellectis - CLLS Stock Forecast, Price & News

$2.24
+0.09 (+4.19%)
(As of 12/8/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.16
$2.27
50-Day Range
$2.07
$2.60
52-Week Range
$2.00
$9.30
Volume
44,459 shs
Average Volume
85,666 shs
Market Capitalization
$102.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.17

Cellectis MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
533.9% Upside
$14.20 Price Target
Short Interest
Healthy
1.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.36mentions of Cellectis in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.67) to ($1.08) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

491st out of 1,022 stocks

Biological Products, Except Diagnostic Industry

82nd out of 171 stocks

CLLS stock logo

About Cellectis (NASDAQ:CLLS) Stock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Stock News Headlines

Cellectis (NASDAQ:CLLS) Rating Increased to Hold at StockNews.com
Form 424B5 Calyxt, Inc. - StreetInsider.com
Form 6-K Cellectis S.A. For: Sep 22 - StreetInsider.com
See More Headlines
Receive CLLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter.

CLLS Company Calendar

Last Earnings
12/08/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/02/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLLS
Employees
294
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$14.20
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+577.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-114,200,000.00
Net Margins
-470.32%
Pretax Margin
-511.95%

Debt

Sales & Book Value

Annual Sales
$67.07 million
Book Value
$5.20 per share

Miscellaneous

Free Float
38,090,000
Market Cap
$102.08 million
Optionable
Optionable
Beta
1.99

Key Executives

  • Dr. Andre Choulika Ph.D. (Age 57)
    Co-Founder, CEO & Director
    Comp: $879.06k
  • Dr. David J. D. Sourdive Ph.D. (Age 55)
    Director, Deputy CEO, Exec. VP of CMC and Manufacturing
    Comp: $580.28k
  • Dr. Bing C. Wang M.B.A. (Age 45)
    Ph.D., Chief Financial Officer
  • Valerie Cros
    Principal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat
    Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D. (Age 59)
    Chief Scientific Officer
  • Mr. Stephan Reynier M.Sc. (Age 53)
    MSc, Chief Regulatory & Pharmaceutical Compliance Officer
  • Ms. Marie-Bleuenn Terrier (Age 40)
    Gen. Counsel & Sec. of the Board of Directors
  • Pascalyne Wilson
    Director of Communications
  • Ms. Kyung Nam-Wortman (Age 52)
    Exec. VP & Chief HR Officer













CLLS Stock - Frequently Asked Questions

Should I buy or sell Cellectis stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLLS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLLS, but not buy additional shares or sell existing shares.
View CLLS analyst ratings
or view top-rated stocks.

What is Cellectis' stock price forecast for 2023?

4 Wall Street analysts have issued 1 year price objectives for Cellectis' stock. Their CLLS share price forecasts range from $2.00 to $36.00. On average, they expect the company's share price to reach $14.20 in the next twelve months. This suggests a possible upside of 533.9% from the stock's current price.
View analysts price targets for CLLS
or view top-rated stocks among Wall Street analysts.

How have CLLS shares performed in 2022?

Cellectis' stock was trading at $8.12 at the beginning of the year. Since then, CLLS stock has decreased by 72.4% and is now trading at $2.24.
View the best growth stocks for 2022 here
.

Are investors shorting Cellectis?

Cellectis saw a drop in short interest in November. As of November 15th, there was short interest totaling 526,300 shares, a drop of 9.3% from the October 31st total of 580,400 shares. Based on an average daily trading volume, of 83,200 shares, the days-to-cover ratio is presently 6.3 days. Currently, 1.2% of the shares of the stock are short sold.
View Cellectis' Short Interest
.

When is Cellectis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our CLLS earnings forecast
.

How were Cellectis' earnings last quarter?

Cellectis S.A. (NASDAQ:CLLS) released its earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.82) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by $0.02. Cellectis had a negative net margin of 470.32% and a negative trailing twelve-month return on equity of 54.50%.

What is André Choulika's approval rating as Cellectis' CEO?

13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend.

What other stocks do shareholders of Cellectis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE).

When did Cellectis IPO?

(CLLS) raised $129 million in an IPO on Wednesday, March 25th 2015. The company issued 3,500,000 shares at $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Long Focus Capital Management LLC (5.89%), Baillie Gifford & Co. (1.73%), Jane Street Group LLC (0.75%), BlackRock Inc. (0.62%), State Street Corp (0.58%) and Marshall Wace LLP (0.24%).

How do I buy shares of Cellectis?

Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $2.24.

How much money does Cellectis make?

Cellectis (NASDAQ:CLLS) has a market capitalization of $102.07 million and generates $67.07 million in revenue each year. The biotechnology company earns $-114,200,000.00 in net income (profit) each year or ($2.30) on an earnings per share basis.

How many employees does Cellectis have?

The company employs 294 workers across the globe.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The official website for the company is www.cellectis.com. The biotechnology company can be reached via phone at (318) 169-1600, via email at investors@cellectis.com, or via fax at 33-1-81-69-16-06.

This page (NASDAQ:CLLS) was last updated on 12/9/2022 by MarketBeat.com Staff